Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma

Image credit: CLC


The prognostic value of different KRAS (Kirsten rat sarcoma viral oncogene) mutation subtypes and their association with programmed death ligand 1 (PD-L1) expression in lung adenocarcinoma (LADC) remain unclear. We examined the association of KRAS mutation subtypes with clinical outcomes and PD-L1 expression status.

Clinical Lung Cancer
Yuan Du
Yuan Du
Senior Data Scientist

My interests include applied Statistics, Machine Learning, Deep Learning and Healthcare.